SM
BTAI icon

SG3 Management’s BioXcel Therapeutics BTAI Stock Holding History

SG3 Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-938
Closed -$693K – 1195
2020
Q4 		$693K Buy
+938
New +$731K 0.01% 650

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SG3 Management's BTAI Position: Q1 2021 in Review

SG3 Management sold out of BioXcel Therapeutics (BTAI) in Q1 2021, closing a stake of 938 shares — an estimated $693K sold.

SG3 Management first reported a position in BTAI in Q4 2020 and held it in 1 quarter. The position peaked at $693K in Q4 2020. 116 funds tracked by Wall St. Rank hold BTAI as of Q1 2021.

  • SG3 Management reported no remaining BioXcel Therapeutics position as of Q1 2021 after selling out during the quarter.
  • SG3 Management sold 938 BioXcel Therapeutics shares in Q1 2021, an estimated $693K.
  • SG3 Management first reported a position in BioXcel Therapeutics in Q4 2020 and held it in 1 quarter.
  • SG3 Management's BioXcel Therapeutics position peaked at $693K in Q4 2020.
  • 116 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2021.

Based on SG3 Management's 13F filing for Q1 2021, filed 17 May 2021.